Tolvaptan increases urine and ultrafiltration volume for patients with oliguria undergoing peritoneal dialysis.

Background: Hypoalbuminemia caused by peritoneal dialysate protein loss, frequently occurs in patients on peritoneal dialysis (PD) and is associated with an increased risk of death. We investigate whether PD dialysis exchange volume (PD volume) could be reduced with tolvaptan (TVP) through increased urine volume (UV).

Methods: The study included 11 stable patients with oliguria undergoing PD.